Entrectinib, the kinase inhibitor drug initially discovered and developed by Nerviano Medical Sciences approved by AIFA in two oncology indications

Entrectinib, the kinase inhibitor drug that was initially discovered and developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has received approval for marketing and reimbursement from the Italian drug agency AIFA in two oncology indications: lung cancer ROS1 kinase fusion positive, and any solid […]

CPhI Worldwide

Where: Fiera Milano, Milan, Italy When: 9 November – 11 November 2021   CPhI Worldwide 2021 has established itself as the flagship event for the pharmaceutical industry. The upcoming edition of the expo will be staged from 9th to 11th of November at Fiera Milano. The organizers expect an even bigger gathering of professionals and […]

Accelera and BiomimX: Commercial agreement

Nerviano, 30 June 2021 Accelera Srl and BiomimX® Srl have signed a non-exclusive commercial agreement following an intense scientific collaboration aimed at introducing and applying new technological solutions to the drug discovery process. The commercial agreement between the Companies determines that Accelera proposes within its commercial offer BiomimX®’s technological solutions: uHeart and uKnee. uHeart, is […]

Share this page

Facebook
Twitter
LinkedIn
Email
svg.e-font-icon-svg {display:none!important} .elementor-button-icon {display:none!important} .show-more, .show-more2 {display:none!important} img.pf-large-image.pf-primary-img.flex-width.pf-size-full.blockImage { display: none!important; }